Bruker has launched a new software solution, BioPharmaCompass 1.1 to encompass the complete biopharmaceutical characterization challenge, which includes glycoforms, impurities and modifications.
The software allows biotech customers to leverage Bruker's mass spectrometry for intact protein and post-translational modification analysis in a routine industrial biologics environment.
The solution introduced techniques for a complete picture of biological products for regulatory approval and compliance such as intact precise-mass product confirmation and impurity identification, antibody determination by top-down sequencing, glycan profiling, PTM and artifact determination, rapid identity testing.
BioPharmaCompass 1.1 also features automatic combination of data from multiple enzymatic approaches and Glycoquest complete glycoprotein analysis solution and integrated library.
Bruker Daltonics Life Science Mass Spectrometry division president Ian Sanders said "The speed and completeness of the analytical picture is vital to our customers securing regulatory approval in this rapidly growing market."
Pierre Fabre Center of Immunology Antibody Physico-Chemistry senior director Alain Beck said, "We had a chance to work with Bruker's scientists on antibody characterization by Mass Spectrometry including the use of BioPharmaCompass."
The new development is also expected to deliver increased productivity in the industrial environment.
